China's Centre for Drug Evaluation (CDE) has proposed priority review for daraxonrasib, licensed by BeOne from Revolution Medicines, for adults with metastatic pancreatic cancer who have received at least one prior systemic therapy or are unsuitable for multi-agent regimens. The oral, non-covalent, multi-selective RAS(ON) inhibitor blocks wild-type and mutant RAS signalling across KRAS, NRAS and HRAS variants, addressing the roughly 90% of pancreatic ductal adenocarcinoma (PDAC) patients who carry RAS mutations and have historically had few targeted options.
The clinical case is strong. In the Phase III RASolute 302 study, daraxonrasib extended median progression-free survival to 7.2 months versus 3.6 months for chemotherapy, a hazard ratio of 0.49, and median overall survival to 13.2 months versus 6.7 months, a hazard ratio of 0.40, supporting the US approval granted in August under the Rasonque brand and USD 198 million in revenue within five weeks of launch.
Cutaneous toxicity affects 86% of treated patients, with 10% at grade 3, requiring prophylactic management, but the benefit-risk profile remains compelling.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation